Support to Launch HIV Cure Study-GETRIDDAVIR
HIV/AIDS remains one of the most pressing global health challenges, currently affecting approximately 40 million people worldwide. While combination antiretroviral therapy (ART) can effectively halt the progression of the disease, discontinuing the therapy results in the rapid return of the virus. This highlights the urgent need for a definitive, long-term solution—a permanent cure for HIV/AIDS.
In response to this critical need, the Hawaii Center for AIDS, in collaboration with the Italian National Institute of Health, the University of Bristol, and Weill Cornell University, is launching a groundbreaking early-phase clinical trial. This trial, named GlutathionE Thwarting and RIDaura: Double Attack on the Viral Reservoir (GETRIDDAVIR), aims to test a revolutionary combination of 2 drugs, one of which is investigational, designed to selectively target and eliminate the hidden HIV reservoirs that persist during ART. We have now obtained the investigational drug from the U.S. National Cancer Institute, but before we can conduct the clinical trial, we have a need for further product development and testing.
We are therefore seeking your generous support to make this pioneering research a reality. Contributions can be made to the UH Foundation ‘Hawaii 2 Zero’ Account #127-2460-4. Your donation will directly support this innovative study, bringing us one step closer to a world free of HIV/AIDS.
Thank you for considering this critical opportunity to make a lasting impact.